Incyte
NEWS
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
It was a moderately busy week for clinical trial news. Here’s a look.
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Jakafi hit the mark, meeting the trial’s primary endpoint of superior overall response rate (ORR) at Week 24 compared to best available therapy (BAT).
JOBS
IN THE PRESS